Welcome to our dedicated page for VitaNova Life Sciences SEC filings (Ticker: VNOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VitaNova Life Sciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VitaNova Life Sciences's regulatory disclosures and financial reporting.
VitaNova Life Sciences Corporation (VNOV) reported a sharp revenue increase but lower profitability for the quarter ended July 31, 2026. Revenue rose to $321,576 from $103,899 a year earlier, driven mainly by the new healthy food products line, which contributed $234,576 of sales.
Despite higher sales, gross profit fell to $30,521 from $68,781 and gross margin dropped to 9% from 66%, as food products carried only about a 3% margin and dietary supplement sales declined. Net loss widened to $123,101 from $46,301, and cash from operating activities decreased to $6,965 from $263,811.
The company ended the quarter with $1,604,182 in cash, total assets of $2,239,335, and total liabilities of $311,656, with no preferred stock outstanding and 8,337,454 common shares issued and outstanding. Management identified material weaknesses in internal control, including the absence of an audit committee and insufficient qualified accounting personnel, though it believes current cash and operating cash flows will cover working capital needs for the next 12 months.
VitaNova Life Sciences Corporation, a Nevada-based consumer health company, sells dietary supplements under its GeneCode and AMZ brands and, since 2026, healthy food products through VitaNova Global Foods, plus a small consulting business. Revenue for the year ended April 30, 2026 was $3,025,538, including $1,947,620 from supplements, $1,062,918 from food products and $15,000 from consulting.
Gross profit was $910,589, with margin compressing to 30% from 59% as lower-margin food products and promotional pricing offset growth. General and administrative expenses increased to $733,795, largely from higher legal, professional and stock-compensation costs, resulting in a net loss of $37,304 versus prior-year net income of $850,746. The company generated $814,407 of operating cash flow, ended the year with $1,597,217 in cash and total current liabilities of $395,781, and had 8,337,454 common shares outstanding. Revenue is concentrated in a small number of customers and suppliers, and operations rely on third-party manufacturers operating under U.S. dietary-supplement and food-safety regulations.
VitaNova Life Sciences Corporation reported a board change. Effective March 12, 2026, Ruiming Zhou resigned from her position as a director of the company. The company states that Ms. Zhou’s resignation was not due to any disagreement regarding VitaNova’s operations, policies, or practices.
VitaNova Life Sciences Corporation reported sharply higher sales but moved into a small loss for the quarter and nine months ended January 31, 2026. Revenue reached $709,625 for the quarter and $1,240,639 for nine months, increases of 130% and 75% driven by its dietary supplement segment. Gross profit rose, but margins narrowed as cost of revenue grew faster than sales and general and administrative expenses climbed to $405,339 for nine months, largely from higher legal and professional fees. The company posted net losses of $44,362 for the quarter and $54,853 year‑to‑date, compared with profits a year earlier, and recorded an effective tax rate above the statutory level. Cash improved to $1,168,904 with operating cash flow of $386,094, and shareholders’ equity was $1,853,831 with 8,337,454 common shares outstanding as of March 11, 2026. Management highlights continued material weaknesses in internal controls and a high dependence on a few customers and a single vendor, while also noting a recent name change, a 1‑for‑3 reverse stock split, and formation of a new wholly owned subsidiary, VitaNova Global Foods Corporation.